Traynor Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Traynor Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,005	Closed	-$210K	–	124
2015 Q4	$210K	Sell	2,005 -50	-2%	-$5.22K	0.15%	117
2015 Q3	$216K	Hold	2,055	–	–	0.19%	102
2015 Q2	$281K	Hold	2,055	–	–	0.23%	95
2015 Q1	$256K	Buy	+2,055	New	+$218K	0.25%	88

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Traynor Capital Management's BMRN Position: Q1 2016 in Review

Traynor Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 2,005 shares — an estimated $210K sold.

Traynor Capital Management first reported a position in BMRN in Q1 2015 and held it in 4 quarters. The position peaked at $281K in Q2 2015. 390 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Traynor Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Traynor Capital Management sold 2,005 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $210K.
Traynor Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 4 quarters.
Traynor Capital Management's BioMarin Pharmaceuticals position peaked at $281K in Q2 2015.
390 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Traynor Capital Management's 13F filing for Q1 2016, filed 18 Apr 2016.